A Phase 3 interventional study of Entecavir and Tenofovir in Chronic Hepatitis B, sponsored by Bristol-Myers Squibb. Completed at 28 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-15.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.
Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 24th largest by enrollment of the 61 interventional ones that give a count, is one of 6 that started in 2010, is one of 13 in phase 3, and was the 29th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:
Ascentage Pharma Group Inc. · Sites in China
Ages 18+
Qing-Lei Zeng
Ages 3–6
Qing-Lei Zeng
Ages 3–6
By country, each count listing its studies:
entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 13 · Phase 4 33
First in 2001; this study’s year is marked. 6 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 144 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 109 across the 61 interventional studies. Of the 40 that completed or were terminated, 15 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 64 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
24 studies in Hepatitis B, Chronic by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 23 finished, 11 (48%) have results posted.
Among the 24 studies in Hepatitis B, Chronic by Bristol-Myers Squibb, this one is the 7th largest by enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2010, is one of 11 in phase 3, and was the 19th registered.
Bristol-Myers Squibb’s Hepatitis B, Chronic studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 64 studies testing entecavir in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 24 in Hepatitis B, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to show that the combination of entecavir and tenofovir, is effective and well tolerated in chronic hepatitis B patients who have failed previous treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Entecavir · Drug: Tenofovir
Percentage of Participants With a Virologic Response at Week 48 - Treated Population
Virologic response was defined as Hepatitis B virus (HBV) Deoxyribonucleic acid (DNA) less than 50 international units per milliliter (IU/mL); approximately 300 copies/mL. Percentage was calculated as number of participants with virologic response at Week 48 divided by the number of treated participants. Treated participants were evaluated using non-completer (NC) = failure (F). The HBV DNA by polymerase chain reaction (PCR) was measured using the Roche COBAS(REGISTERED) TaqMan - High Pure System (HPS) assay, in a central laboratory. The results were reported in IU/mL, with the limit of quantification (LOQ) = 29 IU/mL and lower limit of detection (LLD) = 6 IU/mL. HBV DNA measurements were transformed by the log10 scale when analyzed as a continuous variable, using log10(LOQ-1) for values below LOQ.
Time frame: Week 48
Percentage of Participants With a Virologic Response at Week 24 and at Week 96 - Treated Population
Virologic response was defined as Hepatitis B virus (HBV) Deoxyribonucleic acid (DNA) less than 50 international units per milliliter (IU/mL); approximately 300 copies/mL. Percentage was calculated as number of participants with virologic response at Week 24, Week 96 divided by the number of treated participants. Treated participants were evaluated using non-completer (NC) = failure (F). The HBV DNA by polymerase chain reaction (PCR) was measured using the Roche COBAS(REGISTERED) TaqMan - High Pure System (HPS) assay. The results were reported in IU/mL, with the limit of quantification (LOQ) = 29 IU/mL and lower limit of detection (LLD) = 6 IU/mL. HBV DNA measurements were transformed by the log10 scale when analyzed as a continuous variable, using log10(LOQ-1) for values below LOQ.
Time frame: Week 24, Week 96
Change From Baseline in Mean log10 HBV DNA at Weeks 12, 24, 48, and 96 - Treated Evaluable Population
HBV DNA by polymerase chain reaction (PCR) was measured using the Roche COBAS(REGISTERED) TaqMan - High Pure System (HPS) assay. The results were reported in log 10 IU/mL, with the limit of quantification (LOQ) = 29 IU/mL and lower limit of detection (LLD) = 6 IU/mL. HBV DNA measurements were transformed by the log10 scale when analyzed as a continuous variable, using log10(LOQ-1) for values below LOQ. Baseline was Day 1, prior to study drug administration.
Time frame: Baseline to Weeks 12, 24, 48, 96
Percentage of Participants With HBV DNA Less Than the Lower Limit of Detection (LLD) at Weeks 24, 48, and 96 - Treated Population
HBV DNA less than (\<) LLD (6 IU/mL) was defined/measured by the COBAS(REGISTERED) TaqMan HPS assay at Weeks 24, 48, and 96. Percentage was calculated as number of participants with HBV DNA \< LLD at Weeks 24, 48, 96 divided by the number of treated participants. Treated participants were evaluated using non-completer (NC) = failure (F).
Time frame: Weeks 24, 48, 96
Percentage of Participants With Hepatitis B e Antigen (HBeAg) Loss at Weeks 24, 48, and 96 - Treated Population Who Were HBeAg Positive at Baseline
Loss of HBeAg was defined as being HBeAg-negative at Weeks 24, 48, and 96 in those participants who had been HBeAg-positive at baseline. Method used for HBeAg was DiaSorin - Anti HBe enzyme immunoassay kit - procedure for qualitative determination of antibodies to HBeAg in human serum or plasma samples. Percentage was calculated as number of participants with HBeAg loss at Weeks 24 and 48 divided by the number of treated participants who were HBeAg-positive at baseline. Treated participants (HBeAg-positive at baseline) were evaluated using NC = F. Baseline was Day 1, before start of study drug.
Time frame: Baseline to Weeks 24, 48, and 96
Percentage of Participants With HBe Seroconversion at Weeks 24, 48, and 96 - Treated Population Who Were HBeAg-positive at Baseline
HBe seroconversion was defined as being both HBeAg-negative and HBeAb-positive at Weeks 24, 48, and 96 in those participants who had been HBeAg-positive at baseline. Method used was DiaSorin - Anti HBe enzyme immunoassay kit - procedure for qualitative determination of antibodies to HBeAg in human serum or plasma samples. Percentage was calculated as number of participants with HBe seroconversion at Weeks 24, 48, and 96 divided by the number of treated participants who were HBeAg-positive at baseline. Treated participants (HBeAg-positive at baseline) were evaluated using NC = F. Baseline was Day 1, before start of study drug.
Time frame: Baseline, Weeks 24, 48, and 96
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Loss at Weeks 24, 48, 96 - Treated Population Who Were HBsAg-Positive at Baseline
Loss of HBsAg was defined as being HBsAg-negative at Weeks 24, 48, 96 in those participants who had been HBsAg-positive at baseline. The method used: Immunoassay - ADVIA CENTAUR from SIEMENS: in vitro diagnostic immunoassay for the qualitative and quantitative determination of HBsAg in human serum and plasma (potassium ethylene diamine tetraacetic acid, lithium or sodium heparinized). Percentage calculated as number of participants with a HBsAg loss at Weeks 24, 48, and 96 divided by the number of treated participants who were HBsAg-positive at baseline (participants were not enrolled into the study unless they were positive for HBsAg). Treated participants (HBsAg-positive at baseline) were evaluated using NC=F. Baseline was Day 1, before start of study drug.
Time frame: Baseline, Weeks 24, 48, 96
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Seroconversion at Weeks 24, 48, and 96 - Treated Population Who Were HBsAg-Positive at Baseline
HBsAg seroconversion was defined as being both HBsAg-negative and HBsAb-positive at Weeks 24, 48, and 96 in those participants who had been HBsAg-positive at baseline. Percentage was calculated as number of participants with HBs seroconversion at Weeks 24 and 48 divided by the number of treated participants who were HBsAg-positive at baseline. Positive result for HBsAg was one of the inclusion criteria. Treated participants (HBsAg positive at baseline) were evaluated using NC=F. The method used was an Immunoassay testing - ADVIA CENTAUR from SIEMENS: in vitro diagnostic immunoassay for the qualitative and quantitative determination of HBsAg in human serum and plasma \[potassium ethylenediaminetetraacetic acid (EDTA), lithium or sodium heparinized\]. Baseline was Day 1, before start of study drug.
Time frame: Baseline, Weeks 24, 48, and 96
Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) on Treatment, and Discontinuation of Study Drug Due to Adverse Events (AE) - Treated Population
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. On-treatment = on Day 1 through last dose of study therapy + 5 days.
Time frame: Day 1 to last dose of study drug plus 5 days; up to Week 96
Number of Participants With Emergence of Genotypic Resistance to Study Drugs at Weeks 48 and 96- Treated Population
Testing of HBV genotype was performed at baseline for all treated patients and for participants at Weeks 48 and 96 with primary non-response or virologic breakthrough. Emergent genotypic resistance to study drugs was defined as follows: Emergent = not detected at baseline; entecavir (ETV) resistance (ETVr): participant's sample was to have rtM204V/I/S and any substitution at rtT184, rtS202, or rtM250; tenofovir (TDF) resistance (TDFr) which was based on adefovir (ADV)-mutations: participant's sample was to have rtA181T/V, rtN236T, or (rtA194T and rtM204V/I/S). Primary non-response was defined as \< 1 log10 decrease in HBV DNA from baseline on treatment at or after Week 12. Virologic breakthrough was defined as ≥ 1 log10 increase in HBV DNA over nadir on treatment, either confirmed or last on-treatment followed by discontinuation of study therapy.
Time frame: Baseline to Weeks 48, 96
Number of Participants on Treatment With Study Drug With Laboratory Test Abnormalities Meeting Selected Criteria on Treatment - Treated Population
Selected criteria presented in each category. Upper limit of normal among all laboratory ranges (ULN); Baseline (BL); alanine transaminase (ALT); milligram per deciliter (mg/dL); milliliters per minute (mL/min); greater than (\>);greater than, equal to (\>=); less than (\<). Creatinine data presented below were confirmed, ie, at least 2 consecutive values. On-treatment = after Day 1 through last dose of study therapy + 5 days.
Time frame: Day 1 to last dose of study drug plus 5 days; up to Week 96
Study initiated 17 May 2010; Week 48 Primary Endpoint 27 November 2012; Week 96 Study Completed18 February 2014. Participants with chronic Hepatitis B with surface antigen (HBsAg) who have been currently treated and experienced treatment failure were enrolled.
| Milestone | Entecavir + Tenofovir |
|---|---|
| Started | 92 |
| Completed | 86 |
| Not completed | 6 |
| Withdrew: Adverse event | 1 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Pregnancy | 1 |
| Milestone | Entecavir + Tenofovir |
|---|---|
| Started | 85 |
| Completed | 46 |
| Not completed | 39 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Alternative therapy started | 32 |
Virologic response was defined as Hepatitis B virus (HBV) Deoxyribonucleic acid (DNA) less than 50 international units per milliliter (IU/mL); approximately 300 copies/mL. Percentage was calculated as number of participants with virologic response at Week 48 divided by the number of treated participants. Treated participants were evaluated using non-completer (NC) = failure (F). The HBV DNA by polymerase chain reaction (PCR) was measured using the Roche COBAS(REGISTERED) TaqMan - High Pure System (HPS) assay, in a central laboratory. The results were reported in IU/mL, with the limit of quantification (LOQ) = 29 IU/mL and lower limit of detection (LLD) = 6 IU/mL. HBV DNA measurements were transformed by the log10 scale when analyzed as a continuous variable, using log10(LOQ-1) for values below LOQ.
| percentage of participants | Entecavir + Tenofovir |
|---|---|
| Percentage of Participants With a Virologic Response at Week 48 - Treated Population | 76.1 (66.1 to 84.4) |
Virologic response was defined as Hepatitis B virus (HBV) Deoxyribonucleic acid (DNA) less than 50 international units per milliliter (IU/mL); approximately 300 copies/mL. Percentage was calculated as number of participants with virologic response at Week 24, Week 96 divided by the number of treated participants. Treated participants were evaluated using non-completer (NC) = failure (F). The HBV DNA by polymerase chain reaction (PCR) was measured using the Roche COBAS(REGISTERED) TaqMan - High Pure System (HPS) assay. The results were reported in IU/mL, with the limit of quantification (LOQ) = 29 IU/mL and lower limit of detection (LLD) = 6 IU/mL. HBV DNA measurements were transformed by the log10 scale when analyzed as a continuous variable, using log10(LOQ-1) for values below LOQ.
| percentage of participants | Entecavir + Tenofovir |
|---|---|
| Week 24 (n=92) | 64.1 (53.5 to 73.9) |
| Week 96 (n=92) | 84.8 (75.8 to 91.4) |
HBV DNA by polymerase chain reaction (PCR) was measured using the Roche COBAS(REGISTERED) TaqMan - High Pure System (HPS) assay. The results were reported in log 10 IU/mL, with the limit of quantification (LOQ) = 29 IU/mL and lower limit of detection (LLD) = 6 IU/mL. HBV DNA measurements were transformed by the log10 scale when analyzed as a continuous variable, using log10(LOQ-1) for values below LOQ. Baseline was Day 1, prior to study drug administration.
| log10 IU/mL | Entecavir + Tenofovir |
|---|---|
| Week 12 (n=89) | -2.230 ± 1.5339 |
| Week 24 (n=89) | -2.581 ± 1.8019 |
| Week 48 (n=88) | -2.829 ± 2.0537 |
| Week 96 (n=84) | -2.965 ± 2.1431 |
HBV DNA less than (\<) LLD (6 IU/mL) was defined/measured by the COBAS(REGISTERED) TaqMan HPS assay at Weeks 24, 48, and 96. Percentage was calculated as number of participants with HBV DNA \< LLD at Weeks 24, 48, 96 divided by the number of treated participants. Treated participants were evaluated using non-completer (NC) = failure (F).
| percentage of participants | Entecavir + Tenofovir |
|---|---|
| Week 24 (n=92) | 12.0 (6.1 to 20.4) |
| Week 48 (n=92) | 18.5 (11.1 to 27.9) |
| Week 96 (n=92) | 16.3 (9.4 to 25.5) |
Loss of HBeAg was defined as being HBeAg-negative at Weeks 24, 48, and 96 in those participants who had been HBeAg-positive at baseline. Method used for HBeAg was DiaSorin - Anti HBe enzyme immunoassay kit - procedure for qualitative determination of antibodies to HBeAg in human serum or plasma samples. Percentage was calculated as number of participants with HBeAg loss at Weeks 24 and 48 divided by the number of treated participants who were HBeAg-positive at baseline. Treated participants (HBeAg-positive at baseline) were evaluated using NC = F. Baseline was Day 1, before start of study drug.
| percentage of participants | Entecavir + Tenofovir |
|---|---|
| Week 24 (n=56) | 3.6 (0.4 to 12.3) |
| Week 48 (n=56) | 5.4 (1.1 to 14.9) |
| Week 96 (n=56) | 8.9 (3.0 to 19.6) |
HBe seroconversion was defined as being both HBeAg-negative and HBeAb-positive at Weeks 24, 48, and 96 in those participants who had been HBeAg-positive at baseline. Method used was DiaSorin - Anti HBe enzyme immunoassay kit - procedure for qualitative determination of antibodies to HBeAg in human serum or plasma samples. Percentage was calculated as number of participants with HBe seroconversion at Weeks 24, 48, and 96 divided by the number of treated participants who were HBeAg-positive at baseline. Treated participants (HBeAg-positive at baseline) were evaluated using NC = F. Baseline was Day 1, before start of study drug.
| percentage of participants | Entecavir + Tenofovir |
|---|---|
| Week 24 (n=56) | 3.6 (0.4 to 12.3) |
| Week 48 (n=56) | 3.6 (0.4 to 12.3) |
| Week 96 (n=56) | 1.8 (0.0 to 9.6) |
Loss of HBsAg was defined as being HBsAg-negative at Weeks 24, 48, 96 in those participants who had been HBsAg-positive at baseline. The method used: Immunoassay - ADVIA CENTAUR from SIEMENS: in vitro diagnostic immunoassay for the qualitative and quantitative determination of HBsAg in human serum and plasma (potassium ethylene diamine tetraacetic acid, lithium or sodium heparinized). Percentage calculated as number of participants with a HBsAg loss at Weeks 24, 48, and 96 divided by the number of treated participants who were HBsAg-positive at baseline (participants were not enrolled into the study unless they were positive for HBsAg). Treated participants (HBsAg-positive at baseline) were evaluated using NC=F. Baseline was Day 1, before start of study drug.
| percentage of participants | Entecavir + Tenofovir |
|---|---|
| Week 24 (n=92) | 1.1 (0.0 to 5.9) |
| Week 48 (n=92) | 0 (NA to NA) |
| Week 96 (n=92) | 2.2 (0.3 to 7.6) |
HBsAg seroconversion was defined as being both HBsAg-negative and HBsAb-positive at Weeks 24, 48, and 96 in those participants who had been HBsAg-positive at baseline. Percentage was calculated as number of participants with HBs seroconversion at Weeks 24 and 48 divided by the number of treated participants who were HBsAg-positive at baseline. Positive result for HBsAg was one of the inclusion criteria. Treated participants (HBsAg positive at baseline) were evaluated using NC=F. The method used was an Immunoassay testing - ADVIA CENTAUR from SIEMENS: in vitro diagnostic immunoassay for the qualitative and quantitative determination of HBsAg in human serum and plasma \[potassium ethylenediaminetetraacetic acid (EDTA), lithium or sodium heparinized\]. Baseline was Day 1, before start of study drug.
| percentage of participants | Entecavir + Tenofovir |
|---|---|
| Week 24 (n=92) | 1.1 (0.0 to 5.9) |
| Week 48 (n=92) | 0 (NA to NA) |
| Week 96 (n=92) | 1.1 (0.0 to 5.9) |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. On-treatment = on Day 1 through last dose of study therapy + 5 days.
| participants | Entecavir + Tenofovir |
|---|---|
| Treatment emergent SAE | 6 |
| Discontinuation of treatment due to AE | 1 |
Testing of HBV genotype was performed at baseline for all treated patients and for participants at Weeks 48 and 96 with primary non-response or virologic breakthrough. Emergent genotypic resistance to study drugs was defined as follows: Emergent = not detected at baseline; entecavir (ETV) resistance (ETVr): participant's sample was to have rtM204V/I/S and any substitution at rtT184, rtS202, or rtM250; tenofovir (TDF) resistance (TDFr) which was based on adefovir (ADV)-mutations: participant's sample was to have rtA181T/V, rtN236T, or (rtA194T and rtM204V/I/S). Primary non-response was defined as \< 1 log10 decrease in HBV DNA from baseline on treatment at or after Week 12. Virologic breakthrough was defined as ≥ 1 log10 increase in HBV DNA over nadir on treatment, either confirmed or last on-treatment followed by discontinuation of study therapy.
| participants | Entecavir + Tenofovir |
|---|---|
| Week 48 (n=5) | 0 |
| Week 96 (n=7) | 0 |
Selected criteria presented in each category. Upper limit of normal among all laboratory ranges (ULN); Baseline (BL); alanine transaminase (ALT); milligram per deciliter (mg/dL); milliliters per minute (mL/min); greater than (\>);greater than, equal to (\>=); less than (\<). Creatinine data presented below were confirmed, ie, at least 2 consecutive values. On-treatment = after Day 1 through last dose of study therapy + 5 days.
| participants | Entecavir + Tenofovir |
|---|---|
| ALT > 2*Baseline(N=90) | 9 |
| ALT > 3*Baseline(N=90) | 2 |
| Total bilirubin >2*Baseline (N=90) | 11 |
| Total bilirubin >3*Baseline (N=90) | 3 |
| Lipase > 3*Baseline (N=90) | 4 |
| Creatinine increase from BL >= 20%(N=91) | 4 |
| Creatinine >1.5 mg/dL (N=91) | 2 |
| Creatinine clearance < 50 mL/min (N=91) | 1 |
| Phosphate < 2.0 mg/dL (N=90) | 2 |
| Phosphate < 2.3 mg/dL (N=90) | 8 |
Collected over Day 1 up to 96 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Entecavir + Tenofovir | — | 6/92 (6.5%) | 42/92 (45.7%) |
| Event | Entecavir + Tenofovir |
|---|---|
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/92 |
| Inguinal herniaGastrointestinal disorders | 1/92 |
| CataractEye disorders | 1/92 |
| AppendicitisInfections and infestations | 1/92 |
| HaemorrhoidsGastrointestinal disorders | 1/92 |
| Radius fractureInjury, poisoning and procedural complications | 1/92 |
| Event | Entecavir + Tenofovir |
|---|---|
| NasopharyngitisInfections and infestations | 11/92 |
| FatigueGeneral disorders | 9/92 |
| NauseaGastrointestinal disorders | 8/92 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/92 |
| DyspepsiaGastrointestinal disorders | 7/92 |
| BronchitisInfections and infestations | 6/92 |
| AstheniaGeneral disorders | 6/92 |
| DiarrhoeaGastrointestinal disorders | 6/92 |
| HeadacheNervous system disorders | 6/92 |
| Abdominal pain upperGastrointestinal disorders | 5/92 |
All participants who were treated with study drug.
| Age, Continuous(years) | Entecavir + Tenofovir |
|---|---|
| Median | 42.0 (18 to 84) |
| Sex: Female, Male(Participants) | Entecavir + Tenofovir |
|---|---|
| Female | 23 |
| Male | 69 |
| Region of Enrollment(participants) | Entecavir + Tenofovir |
|---|---|
| France | 10 |
| Poland | 32 |
| Romania | 20 |
| Germany | 23 |
| Netherlands | 6 |
| Italy | 1 |
| HBV DNA by PCR (log10 IU/mL)(log10 IU/mL) | Entecavir + Tenofovir |
|---|---|
| Median | 3.674 (1.45 to 9.30) |
| Baseline Hepatitis B e Antigen(participants) | Entecavir + Tenofovir |
|---|---|
| Positive for Hepatitis B e antigen | 56 |
| Negative for Hepatitis B e antigen | 34 |
| missing Hepatitis B e antigen test | 2 |
| Baseline Hepatitis B e Antibody(participants) | Entecavir + Tenofovir |
|---|---|
| Positive for Hepatitis B e antibody | 32 |
| Negative for Hepatitis B e antibody | 56 |
| Intermediate Hepatitis B e antibody | 2 |
| missing Hepatitis B e antibody test | 2 |
| Baseline Hepatitis B Surface Antigen(participants) | Entecavir + Tenofovir |
|---|---|
| Positive for Hepatitis B Surface Antigen | 92 |
| Negative for Hepatitis B Surface Antigen | 0 |
| Baseline HBV Subtype(Participants) | Entecavir + Tenofovir |
|---|---|
| HBV Subtype A | 21 |
| HBV Subtype B | 2 |
| HBV Subtype C | 1 |
| HBV Subtype D | 35 |
| HBV Subtype E | 4 |
| HBV Subtype G | 1 |
| HBV Subtype H | 1 |
| HBV Subtype Indeterminate | 3 |
| Insufficient HBV DNA | 23 |
| Missing HBV DNA test | 1 |
1 further baseline measures are reported on the registry.
The record gives a start of May 2010, a primary completion of Nov 2012 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2014, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Entecavir · Tenofovir